SLC5A2 and hydrops fetalis: Lastly, patients participating in the REALITY-AHF were not on the more recently approved life-prolonging HF drugs (endorsed by international guidelines), such as angiotensin receptor neprilysin inhibitor (ARNI) or SGLT2 inhibitors [33,34], since enrollment of these patients took place earlier (2014–2015); therefore, these drugs were not available.